Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Price Target Increased at Stifel Nicolaus

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) had its price target boosted by equities researchers at Stifel Nicolaus from $40.00 to $50.00.Stifel Nicolaus currently has a rating of Buy on the shares. A number of other analysts have commented on the company in recent days, and the company has earned a consensus one-year price target of $46.13, higher than the opening price of $34.62, a difference of 15.07 percent. Aerie Pharmaceuticals Inc. stock has a 52-week high of $34.69.

U.S. stocks finished higher Thursday, near their intra-day highs.

The Dow Jones Industrial Average DJIA, +0.99% closed up 177.71 points, or 1%, at 18,212.48, led by a 3.4% surge in shares of Apple Inc. AAPL, +3.40%

All 30 of the Dow components finished in the green.

The S&P 500 index SPX, +1.01% wrapped up 21.49 points, or 1%, to 2,147.26, and all the large-cap gauge’s sectors ended higher, topped by a 1.7% rise in the tech sector and a 1.1% gain in health-care shares

Stock prices often move to the upside on recommendations and new price targets of professional analysts.

Shares of Aerie Pharmaceuticals Inc. (NASDAQ: AERI) opened at $34.62 yesterday and traded in a range between, $29.60 and $34.69, and last traded at $30.61, which represents a change of $ 9.48 over the previous closing price.

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) now has a market cap of 853.77M

The stocks average daily volume is 686,050 shares out of a total float 13,732,000 and some 16,133,498 shares crossed the trading desk yesterday, 108 percent higher than normal. Significant increases in trading volume and price appreciation together could signal heavy volume accumulation by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these retain substantial teams of analysts that research thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.

By spotting trends, moving averages allow investors to make those trends work in their favor and increase the number of successful trades.

With that in mind Aerie Pharmaceuticals Inc. (NASDAQ: AERI) now has a 50-day MA is $19.35 and 200-day MA is $16.69, and it has traded in a 52-week range between $10.82 – 34.69 and today’s last price is -11.75 percent off the 52 week high of $34.69.

Earnings growth is an important factor to look at when buying stocks and investors look for companies that have grown their earnings at least 25% or more for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of The Woodbridge Citizen. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Add a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.